Analysts warn Bitcoin may drop to $60,000, with clear divergence between bullish and bearish views
ChainCatcher news, according to a report by Cointelegraph, crypto market analyst Michaël van de Poppe stated that Bitcoin has fallen below the critical support range of $75,000 to $76,000. If it fails to reclaim above $76,600, it will be difficult to sustain expectations for a new high, and the price may drop to the $60,000 range. He also pointed out that there are several CME Bitcoin futures gaps above, with the highest above $79,000, and that market pullbacks that occur on Fridays often tend to revert to bullish momentum.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
